The patients receiving AHSCT had 5-year LFS of 46.3% and OS of 53.3%, which were better outcomes than those of the MRC UKALL XII/ECOG E2993 trial conducted from 2006 to 2010.

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

In study, patients with CRC as the only malignancy had more frequent liver and lung metastases and received systemic adjuvant treatments more often.

Patients with intermediate- or high-complexity renal tumors generally have similar outcomes with RAPN and OPN, data suggest.

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.